MIT Scientist to Present at BIO 2015
MIT scientist Robert Langer will speak at BIO 2015 on a panel about venture capitalism in biotechnology.
Robert Langer, MIT scientist and professor, will be speaking on a panel at the BIO International Convention 2015. The panel, Thirty Years of Venture Capitalism in Biotechnology, will take place on June 15, 2015 at 12:30 pm EST and will feature discussions on the history of venture capitalism in biotechnology, how it has shaped the industry, and how it has changed over time. Langer, the 2014 winner of the Biotechnology Heritage Award, which is presented by the Chemical Heritage Foundation every year at BIO Convention, will be joined on the panel by two other winners of this award: Moshe Alafi (2015 winner), a venture capitalist in biotechnology, and Joshua Boger (2011 winner), an entrepreneur and co-founder of Vertex Pharmaceuticals.
For more information on BIO International Convention 2015, please visit BIO 2015. The convention will be held June 15 to June 18, 2015 in Philadelphia, PA at the Philadelphia Convention Center.
Source: BioTech Now
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
In Wake of Trump Tariffs, Lilly Plans New US Pharmaceutical Manufacturing Sites
February 26th 2025Previous domestic capital expansion commitments since 2020 had been made in Research Triangle Park and Concord, both in North Carolina; Kenosha County, Wisconsin; Lebanon, Indiana; and Lilly’s home city of Indianapolis.
Cosette Pharmaceuticals Adds to Dermatology and Women’s Health Portfolio with Mayne Pharma Purchase
Published: February 26th 2025 | Updated: February 26th 2025While the boards of directors of both companies have approved the transaction, it is not expected to close until the second quarter of 2025, as Mayne Pharma’s shareholders must still vote in favor of the acquisition.
FDA Approves First Treatment for Rare Lipid Storage Disease Cerebrotendinous Xanthomatosis
February 24th 2025Cerebrotendinous xanthomatosis, or CTX, is a metabolic disorder caused by a gene mutation that results in a deficiency of an important enzyme in the ability of the human body to break down fats.
